91 related articles for article (PubMed ID: 16013994)
1. Transgenomic's WAVE System used for the early detection of drug resistance mutations in chronic myeloid leukemia.
Pharmacogenomics; 2005 Jul; 6(5):458-9. PubMed ID: 16013994
[No Abstract] [Full Text] [Related]
2. Evidence for D276G and L364I Bcr-Abl mutations in Ph+ leukaemic cells obtained from patients resistant to Imatinib.
Piazza RG; Magistroni V; Gasser M; Andreoni F; Galietta A; Scapozza L; Gambacorti-Passerini C
Leukemia; 2005 Jan; 19(1):132-4. PubMed ID: 15510211
[No Abstract] [Full Text] [Related]
3. Genzyme launches diagnostic to monitor Gleevec resistance.
Pharmacogenomics; 2006 Apr; 7(3):267. PubMed ID: 16610938
[No Abstract] [Full Text] [Related]
4. Y253H mutation appearing in a micro-BCR-ABL (e19a2) CML.
Popovici C; Charbonnier A; Gisserot O; Aguilon P; Rémy V; Olschwang S; Mozziconacci MJ
Leuk Res; 2008 Feb; 32(2):361-2. PubMed ID: 17412419
[No Abstract] [Full Text] [Related]
5. A novel Bcr-Abl splice isoform is associated with the L248V mutation in CML patients with acquired resistance to imatinib.
Gruber FX; Hjorth-Hansen H; Mikkola I; Stenke L; Johansen T
Leukemia; 2006 Nov; 20(11):2057-60. PubMed ID: 17008892
[No Abstract] [Full Text] [Related]
6. Not all imatinib resistance in CML are BCR-ABL kinase domain mutations.
Wei Y; Hardling M; Olsson B; Hezaveh R; Ricksten A; Stockelberg D; Wadenvik H
Ann Hematol; 2006 Dec; 85(12):841-7. PubMed ID: 17006667
[TBL] [Abstract][Full Text] [Related]
7. Detection of BCR-ABL gene mutations in Philadelphia chromosome positive leukemia patients resistant to STI-571 cancer therapy.
Chien JH; Tang JL; Chen RL; Li CC; Lee CP
Leuk Res; 2008 Nov; 32(11):1724-34. PubMed ID: 18603297
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib in chronic myelogenous leukemia.
Chu SC; Tang JL; Li CC
N Engl J Med; 2006 Sep; 355(10):1062-3; author reply 1063-4. PubMed ID: 16960978
[No Abstract] [Full Text] [Related]
9. [Mechanism and overcome against drug resistance to imatinib for treatment of chronic myeloid leukemia].
Tauchi T; Oyashiki K
Gan To Kagaku Ryoho; 2011 May; 38(5):749-53. PubMed ID: 21702118
[No Abstract] [Full Text] [Related]
10. [STI571: the resistance organizes!].
Jeanteur P
Bull Cancer; 2001 Sep; 88(9):819. PubMed ID: 11642306
[No Abstract] [Full Text] [Related]
11. Mutations of the BCR-ABL-kinase domain occur in a minority of patients with stable complete cytogenetic response to imatinib.
Sherbenou DW; Wong MJ; Humayun A; McGreevey LS; Harrell P; Yang R; Mauro M; Heinrich MC; Press RD; Druker BJ; Deininger MW
Leukemia; 2007 Mar; 21(3):489-93. PubMed ID: 17252009
[TBL] [Abstract][Full Text] [Related]
12. Roots of clinical resistance to STI-571 cancer therapy.
Barthe C; Cony-Makhoul P; Melo JV; Mahon JR
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11567109
[No Abstract] [Full Text] [Related]
13. E355G mutation appearing in a patient with e19a2 chronic myeloid leukaemia resistant to imatinib.
Bennour A; Beaufils N; Sennana H; Meddeb B; Saad A; Gabert J
J Clin Pathol; 2010 Aug; 63(8):737-40. PubMed ID: 20702476
[TBL] [Abstract][Full Text] [Related]
14. Use of denaturing HPLC for detection of mutations in the BCR-ABL kinase domain in patients resistant to Imatinib.
Irving JA; O'Brien S; Lennard AL; Minto L; Lin F; Hall AG
Clin Chem; 2004 Jul; 50(7):1233-7. PubMed ID: 15229152
[No Abstract] [Full Text] [Related]
15. Roots of clinical resistance to STI-571 cancer therapy.
Hochhaus A; Kreil S; Corbin A; La Rosée P; Lahaye T; Berger U; Cross NC; Linkesch W; Druker BJ; Hehlmann R; Gambacorti- Passerini C; Corneo G; D'Incalci M
Science; 2001 Sep; 293(5538):2163. PubMed ID: 11569495
[No Abstract] [Full Text] [Related]
16. A mutation conferring resistance to imatinib at the time of diagnosis of chronic myelogenous leukemia.
Roche-Lestienne C; Laï JL; Darré S; Facon T; Preudhomme C
N Engl J Med; 2003 May; 348(22):2265-6. PubMed ID: 12773665
[No Abstract] [Full Text] [Related]
17. The role of serial BCR-ABL transcript monitoring in predicting the emergence of BCR-ABL kinase mutations in imatinib-treated patients with chronic myeloid leukemia.
Wang L; Knight K; Lucas C; Clark RE
Haematologica; 2006 Feb; 91(2):235-9. PubMed ID: 16461309
[TBL] [Abstract][Full Text] [Related]
18. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
Wongboonma W; Thongnoppakhun W; Auewarakul CU
Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
[TBL] [Abstract][Full Text] [Related]
19. Contribution of ABL kinase domain mutations to imatinib resistance in different subsets of Philadelphia-positive patients: by the GIMEMA Working Party on Chronic Myeloid Leukemia.
Soverini S; Colarossi S; Gnani A; Rosti G; Castagnetti F; Poerio A; Iacobucci I; Amabile M; Abruzzese E; Orlandi E; Radaelli F; Ciccone F; Tiribelli M; di Lorenzo R; Caracciolo C; Izzo B; Pane F; Saglio G; Baccarani M; Martinelli G;
Clin Cancer Res; 2006 Dec; 12(24):7374-9. PubMed ID: 17189410
[TBL] [Abstract][Full Text] [Related]
20. p-Stat3 and bcr/abl gene expression in chronic myeloid leukemia and their relation to imatinib therapy.
Sayed D; Badrawy H; Gaber N; Khalaf MR
Leuk Res; 2014 Feb; 38(2):243-50. PubMed ID: 24374144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
